Tags: Drug.
Zalutumumab (proposed trade name HuMax-EGFr) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFr). It is a product developed by Genmab in Utrecht the Netherlands. Specifically zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN) a type of cancer. The current treatment for SCCHN includes tyrosine kinase inhibitors and human monoclonal antibodies.